Second Genome

April 29, 2015April 29, 2015

Industry and Academe Team Up To Develop Microbiome-based Therapies For Patients With Inflammatory Bowel Disease

IBD News, News

San Francisco based Second Genome, Inc., a biotech firm specializing in novel medicine development through applied innovative microbiome science, has formed an alliance with the University College Cork (UCC), Ireland’s ... Read more

February 11, 2015February 12, 2015

Second Genome’s New IBD Drug Advances To Phase 1 Trial

IBD News, News

Second Genome Inc. recently advanced SGM-1019, the company’s primary microbiome drug indicated for inflammatory bowel disease (IBD), to Phase 1 clinical testing to identify an optimal dose. Peter DiLaura, President and the CEO of the company, said ... Read more

October 9, 2014October 9, 2014

Second Genome and Mayo Clinic Partner for Microbiome Treatment Research

Colon Cancer, IBD News, News

Research into some of the world’s most prevalent and deadly gastrointestinal disease is set to take a new turn in researching and developing a new class of therapeutics. A new ... Read more